EZ-editor™ technology (CRISPR based), developed by Ubigene, is more efficient than general
CRISPR/Cas9 technology in double-strand breaking and homologous recombination. With EZ-editor™, Ubigene has
successfully edited over 10000 genes on more than 500 types of cell lines.
Objective
To create a Human CDKN1A Knockout
model in cell line by EZ-editor™-mediated genome engineering.
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of cyclin-dependent kinase2, and may be instrumental in the execution of apoptosis following caspase activation. Mice that lack this gene have the ability to regenerate damaged or missing tissue. Multiple alternatively spliced variants have been found for this gene.
Strategy Summary
This gene has 10 protein coding transcripts：
Transcript
Length(nt)
Protein
Length(aa)
Protein name
Transcript type
Transcript name
ccds
NM_001291549
2378
NP_001278478
198
cyclin-dependent kinase inhibitor 1
3
transcript variant 3
NM_001374509
2286
NP_001361438
198
cyclin-dependent kinase inhibitor 1
3
transcript variant 6
NM_001374510
2140
NP_001361439
177
cyclin-dependent kinase inhibitor 1
3
transcript variant 7
NM_078467
2126
NP_510867
164
cyclin-dependent kinase inhibitor 1
3
transcript variant 2
CCDS4824.1
NM_001220777
2094
NP_001207706
164
cyclin-dependent kinase inhibitor 1
3
transcript variant 5
CCDS4824.1
NM_001220778
2258
NP_001207707
164
cyclin-dependent kinase inhibitor 1
3
transcript variant 4
CCDS4824.1
NM_001374513
2224
NP_001361442
164
cyclin-dependent kinase inhibitor 1
3
transcript variant 10
CCDS4824.1
NM_001374511
2216
NP_001361440
197
cyclin-dependent kinase inhibitor 1
3
transcript variant 8
NM_001374512
2416
NP_001361441
167
cyclin-dependent kinase inhibitor 1
3
transcript variant 9
NM_000389
2117
NP_000380
164
cyclin-dependent kinase inhibitor 1
3
transcript variant 1
CCDS4824.1
Frame-shift
Fragment A
Fragment B
gRNA Detail
Strategy
Project Comprehensive Difficulty Assessment
According to the Red Cotton database: the CRISPR gene-editing strategy design is Unknown. Knockout project comprehensive difficulty is thus assessed as Unknown.
Red Cotton™ Notes
Gene
CDKN1A
had been KO in hct116 cell line.
EZ-editor™ Gene Dependency
EZ-editor™ Gene Expression Level
EZ-editor™ Gene Copy Number
EZ-editor™ Gene Dependency
Result
The CDKN1A gene you inquire is evaluated as high risk
in 0%
cell line.
Cell line is not selected, unable to assess the accurate risk level, for reference only.
In all cell lines, there is
1.1% cells with expression level below cutoff,
16.2% cells with low expression level,
82.7% cells with medium expression level
of CDKN1A gene.
Cell line is not selected, unable to assess the accurate expression level, for reference only.
In all cell lines, there is
59.0% cells with low copy number,
36.6% cells with medium copy number,
4.3% cells with high copy number
of CDKN1A gene.
Cell line is not selected, unable to assess the accurate copy number, for reference only.
Ubigene is an international high-technology enterprise focused on gene-editing cells. Our exclusive EZ-editor™ technology has 10-20 times more efficient editing than traditional methods, easily achieving gene knockout, point mutation, and knock-in. Based on EZ-editor™ technology, Ubigene has accumulated over 6000 successful gene-editing cases from more than 300 cell lines including iPSC and ESC, and has established a KO Cell Line Bank with 5000+ KO cell lines and Red Cotton™ gRNA Plasmid Bank with 10000+ gRNA plasmids available in stock.
Ubigene focuses on technological innovation and product development, of which EZ-editor™ series products that cover the whole workflow of gene-editing keep improving. Ubigene will move on toward our goal of "Make genome editing easier" and we won't stop!
EZ-editor™ Gene Dependency
EZ-editor™ Gene Expression Level 
EZ-editor™ Gene Copy Number 
